Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cited by (128)

Items 101–128 of 128

1. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
   Cunningham, D., Sirohi, B., Pluzanska, A., Utracka-Hutka, B., Zaluski, J., Glynne-Jones, R., Koralewski, P., Bridgewater, J., Mainwaring, P., Wasan, H. et al. · 2009 · Annals of Oncology
2. Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
   Cao, Qing, Tian, Ye, Deng, Zhiyi, Yang, Fangfang, Chen, Erfei · 2024 · International Journal of Molecular Sciences
3. Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in <i>K</i> - <i>Ras</i> Mutant Colorectal and Pancreatic Cancers
   Rosa, Roberta, Melisi, Davide, Damiano, Vincenzo, Bianco, Roberto, Garofalo, Sonia, Gelardi, Teresa, Agrawal, Sudhir, Di Nicolantonio, Federica, Scarpa, Aldo, Bardelli, Alberto et al. · 2011 · Clinical Cancer Research
4. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <i>KRAS</i> -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
   Ahn, Daniel H., Barzi, Afsaneh, Ridinger, Maya, Samuëlsz, Errin, Subramanian, Ramanand A., Wu, Chu-Chiao, Croucher, Peter J.P., Smeal, Tod, Kabbinavar, Fairooz F., Lenz, Heinz-Josef · 2024 · Clinical Cancer Research
5. Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
   Yu, Irene S., Cheung, Winson Y. · 2018 · Canadian Journal of Gastroenterology and Hepatology
6. Molecular pathways: sensitivity and resistance to anti-EGFR antibodies
   Bertotti, Andrea, Sassi, Francesco · 2015 · Clinical Cancer Research
7. In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor Angiogenesis
   Guérin, Eric, Raffelsberger, Wolfgang, Pencreach, Erwan, Maier, Armin, Neuville, Agnès, Schneider, Anne, Bachellier, Philippe, Rohr, Serge, Petitprez, Amélie, Poch, Olivier et al. · 2012 · Molecular Medicine
8. Current and emerging concepts for systemic treatment of metastatic colorectal cancer
   Steup, Christoph, Kennel, Kilian B, Neurath, Markus F, Fichtner-Feigl, Stefan, Greten, Florian R · 2025 · Gut
9. Circulating VEGF Reduction, Response and Outcome in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan
   Vincenzi, Bruno, Santini, Daniele, Russo, Antonio, Gavasci, Michele, Battistoni, Fabrizio, Dicuonzo, Giordano, Rocci, Laura, Rosaria, Valerio Maria, Gebbia, Nicola, Tonini, Giuseppe · 2007 · Pharmacogenomics
10. Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment
    Chen, Ranran, Huang, Yuanjian, Wang, Lu, Zhou, Jiahui, Tan, Yuqian, Peng, Chaofan, Yang, Peng, Peng, Wen, Li, Jie, Gu, Qiou et al. · 2021 · Biomaterials Science
11. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade
    Kasper, S, Breitenbuecher, F, Reis, H, Brandau, S, Worm, K, Köhler, J, Paul, A, Trarbach, T, Schmid, K W, Schuler, M · 2013 · Oncogene
12. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer
    Hong, Chang‐Soo, Sun, Eun‐Gene, Choi, Ji‐Na, Kim, Dae‐Hwan, Kim, Jo‐Heon, Ryu, Kyung‐Hyun, Shim, Hyun‐Jeong, Hwang, Jun‐Eul, Bae, Woo‐Kyun, Kim, Hyeong‐Rok et al. · 2020 · Cancer Science
13. Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent
    Mutsaers, Anthony J., Francia, Giulio, Man, Shan, Lee, Christina R., Ebos, John M.L., Wu, Yan, Witte, Larry, Berry, Scott, Moore, Malcolm, Kerbel, Robert S. · 2009 · Clinical Cancer Research
14. MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling
    Han, Ying, Peng, Yinghui, Fu, Yaojie, Cai, Changjing, Guo, Cao, Liu, Shanshan, Li, Yiyi, Chen, Yihong, Shen, Edward, Long, Kexin et al. · 2020 · Advanced Science
15. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
    Loupakis, Fotios, Cremolini, Chiara, Fioravanti, Anna, Orlandi, Paola, Salvatore, Lisa, Masi, Gianluca, Schirripa, Marta, Di Desidero, Teresa, Antoniotti, Carlotta, Canu, Bastianina et al. · 2014 · Targeted Oncology
16. Causal Evidence and Dispositions in Medicine and Public Health
    Rocca, Elena, Anjum, Rani Lill · 2020 · International Journal of Environmental Research and Public Health
17. The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab
    Strimpakos, Alexios, Pentheroudakis, George, Kotoula, Vassiliki, De Roock, Wendy, Kouvatseas, George, Papakostas, Pavlos, Makatsoris, Thomas, Papamichael, Demetris, Andreadou, Anna, Sgouros, Joseph et al. · 2013 · Clinical Colorectal Cancer
18. <i>In vitro</i> combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells
    Luca, T., Barresi, V., Privitera, G., Musso, N., Caruso, M., Condorelli, D. F., Castorina, S. · 2014 · Cell Proliferation
19. A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
    Bennouna, Jaafar, Deslandres, Marion, Senellart, Helene, de Labareyre, Cecile, Ruiz-Soto, Rodrigo, Wixon, Claire, Botbyl, Jeff, Suttle, A. Benjamin, Delord, Jean-Pierre · 2015 · Investigational New Drugs
20. Production of recombinant immunotherapeutics for anticancer treatment: The role of bioengineering
    Pranchevicius, Maria-Cristina S, Vieira, Thiessa R · 2013 · Bioengineered
21. Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review
    Li, Yong, Chen, Xian, Li, Wenzhu, Ye, Yongsong, Du, Xiaohua, Sun, Shaodan, Liu, Lirong, Zhang, Haibo · 2021 · Frontiers in Oncology
22. Randomised Phase II Study of Panitumumab plus Irinotecan versus Cetuximab plus Irinotecan in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Refractory to Fluoropyrimidine, Irinotecan and Oxaliplatin (WJOG 6510G)
    Sakai, Daisuke, Taniguchi, Hiroya, Sugimoto, Naotoshi, Tamura, Takao, Nishina, Tomohiro, Hara, Hiroki, Esaki, Taito, Denda, Tadamichi, Sakamoto, Takeshi, Okuda, Hiroyuki et al. · 2020 · European Journal of Cancer
23. Current treatment options in RAS mutant metastatic colorectal cancer patients: A meta-analysis of 14 randomized phase III trials
    Stahler, Arndt, Heinemann, Volker, Ricard, Ingrid, von Einem, Jobst C., Giessen-Jung, Clemens, Westphalen, Christoph Benedikt, Michl, Marlies, Heinrich, Kathrin, Miller-Phillips, Lisa, Jelas, Ivan et al. · 2020 · Journal of Cancer Research and Clinical Oncology
24. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models
    Troiani, Teresa, Napolitano, Stefania, Martini, Giulia, Martinelli, Erika, Cardone, Claudia, Normanno, Nicola, Vitagliano, Donata, Morgillo, Floriana, Fenizia, Francesca, Lambiase, Matilde et al. · 2015 · Clinical Cancer Research
25. Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient with Treatment Refractory Metastatic Colorectal Cancer
    Jia, Jingquan, Morse, Michael A., Nagy, Rebecca J., Lanman, Richard B., Strickler, John H. · 2018 · Frontiers in Oncology
26. KRAS, a New Target for Precision Medicine in Colorectal Cancer?
    Boilève, Alice, Smolenschi, Cristina, Lambert, Aurélien, Boige, Valérie, Delaye, Matthieu, Camilleri, Géraldine M., Tarabay, Anthony, Valéry, Marine, Fuerea, Alina, Pudlarz, Thomas et al. · 2024 · Cancers
27. Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
    Al-Hujaily, Ensaf M., Al-Sowayan, Batla S., Alyousef, Zeyad, Uddin, Shahab, Alammari, Farah · 2022 · International Journal of Molecular Sciences
28. EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance
    Abbas, Noura, Mourad, Mohamad, Smaily, Hiba, Al Mahmasani, Layal, Shamseddine, Ali · 2026 · International Journal of Molecular Sciences